Immunogenicity risk management for commercial advantage

Drug Discov Today. 2013 May;18(9-10):417-9. doi: 10.1016/j.drudis.2012.12.010. Epub 2013 Jan 2.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antibody Formation*
  • Arthritis, Rheumatoid / drug therapy
  • Biological Products / adverse effects*
  • Commerce
  • Drug Hypersensitivity*
  • Risk Management / economics
  • T-Lymphocytes, Helper-Inducer / immunology

Substances

  • Biological Products